Literature DB >> 12519875

Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born small for gestational age.

Yvonne van Pareren1, Paul Mulder, Mieke Houdijk, Maarten Jansen, Maarten Reeser, Anita Hokken-Koelega.   

Abstract

Hyperlipidemia, diabetes mellitus type 2, and coronary heart disease have been associated with being born small for gestational age (SGA). It has been reported that GH treatment induced higher insulin levels, which has led to concern regarding the long-term effect of GH treatment in predisposed individuals such as children born SGA. In this study, we assessed the effect of discontinuation of long-term GH treatment in 47 adolescents born SGA on oral glucose tolerance tests, blood pressure (BP), and serum lipid levels for two GH dosage groups (3 vs. 6 IU/m2 x d). At 6 months after discontinuation of GH treatment mean (SD) age was 16.0 (2.1) yr. Mean duration of GH treatment had been 6.9 (1.5) yr. Fasting glucose levels and 120-min area under the curve for glucose 6 months after discontinuation of GH treatment showed no difference from pretreatment levels for both GH dosage groups. After discontinuation of GH treatment, fasting insulin levels returned to pretreatment levels (8.4 mU/liter), whereas the 120-min area under the curve for insulin decreased, compared with 6-yr levels (P < 0.01), regardless of GH dosage group. No significant difference was found when levels were compared with a control group. In addition, for both GH dosage groups, no significant changes in systolic and diastolic BP SD score, total cholesterol, and atherogenic index (total cholesterol/high-density lipoprotein cholesterol) were seen from 6 yr of GH until 6 months after discontinuation of GH treatment. In conclusion, in children born SGA, the GH-induced insulin insensitivity disappeared after discontinuation of GH, even after long-term GH treatment. Furthermore, the beneficial effect of GH on BP was not changed after discontinuation of GH, and most children had normal lipid levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519875     DOI: 10.1210/jc.2002-020458

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Diagnosis and management of Silver-Russell syndrome: first international consensus statement.

Authors:  Emma L Wakeling; Frédéric Brioude; Oluwakemi Lokulo-Sodipe; Susan M O'Connell; Jennifer Salem; Jet Bliek; Ana P M Canton; Krystyna H Chrzanowska; Justin H Davies; Renuka P Dias; Béatrice Dubern; Miriam Elbracht; Eloise Giabicani; Adda Grimberg; Karen Grønskov; Anita C S Hokken-Koelega; Alexander A Jorge; Masayo Kagami; Agnes Linglart; Mohamad Maghnie; Klaus Mohnike; David Monk; Gudrun E Moore; Philip G Murray; Tsutomu Ogata; Isabelle Oliver Petit; Silvia Russo; Edith Said; Meropi Toumba; Zeynep Tümer; Gerhard Binder; Thomas Eggermann; Madeleine D Harbison; I Karen Temple; Deborah J G Mackay; Irène Netchine
Journal:  Nat Rev Endocrinol       Date:  2016-09-02       Impact factor: 43.330

2.  Integrated Digital Health Solutions in the Management of Growth Disorders in Pediatric Patients Receiving Growth Hormone Therapy: A Retrospective Analysis.

Authors:  Vincenzo Tornincasa; David Dixon; Quentin Le Masne; Blaine Martin; Lilian Arnaud; Paula van Dommelen; Ekaterina Koledova
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

Review 3.  Should recombinant human growth hormone therapy be used in short small for gestational age children?

Authors:  L B Johnston; M O Savage
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

4.  Latin American consensus: children born small for gestational age.

Authors:  Margaret C S Boguszewski; Veronica Mericq; Ignacio Bergada; Durval Damiani; Alicia Belgorosky; Peter Gunczler; Teresa Ortiz; Mauricio Llano; Horacio M Domené; Raúl Calzada-León; Armando Blanco; Margarita Barrientos; Patricio Procel; Roberto Lanes; Orlando Jaramillo
Journal:  BMC Pediatr       Date:  2011-07-19       Impact factor: 2.125

5.  Onset of puberty and near adult height in short children born small for gestational age and treated with GH: Interim analysis of up to 10 years of treatment in Japan.

Authors:  Toshiaki Tanaka; Susumu Yokoya; Yoshiki Seino; Hiroshi Tada; Jun Mishina; Takahiro Sato; Shintaro Hiro; Nobuhiko Ohki
Journal:  Clin Pediatr Endocrinol       Date:  2015-02-10

Review 6.  Bridging the gap: metabolic and endocrine care of patients during transition.

Authors:  Anita Hokken-Koelega; Aart-Jan van der Lely; Berthold Hauffa; Gabriele Häusler; Gudmundur Johannsson; Mohamad Maghnie; Jesús Argente; Jean DeSchepper; Helena Gleeson; John W Gregory; Charlotte Höybye; Fahrettin Keleştimur; Anton Luger; Hermann L Müller; Sebastian Neggers; Vera Popovic-Brkic; Eleonora Porcu; Lars Sävendahl; Stephen Shalet; Bessie Spiliotis; Maithé Tauber
Journal:  Endocr Connect       Date:  2016-11-01       Impact factor: 3.335

7.  Effects of size at birth, childhood growth patterns and growth hormone treatment on leukocyte telomere length.

Authors:  Carolina C J Smeets; Veryan Codd; Matthew Denniff; Nilesh J Samani; Anita C S Hokken-Koelega
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

8.  Efficacy and Safety of Up to 8 Years of Long-term Growth Hormone Treatment in Short Children Born Small for Gestational Age in Japan: Analysis of the Subpopulation According to the Japanese Guideline.

Authors:  Toshiaki Tanaka; Susumu Yokoya; Kenji Fujieda; Yoshiki Seino; Hiroshi Tada; Jun Mishina; Susumu Saito; Ami Takata; Nobuhiko Ohki
Journal:  Clin Pediatr Endocrinol       Date:  2012-10-30

9.  Insulin sensitivity obtained from the oral glucose tolerance test and its relationship with birthweight.

Authors:  Yildiz Dallar; Dilek Dilli; Ilknur Bostanci; Elmas Oğüş; Seyda Doğankoç; Egemen Tuğ
Journal:  Ann Saudi Med       Date:  2007 Jan-Feb       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.